Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632748 | 0.83 | MRGPRX4 (0.42) | MRGPRX4LMNA | |
| SCHEMBL23480907 | 0.79 | SLC22A12 (0.46) | XDHSLC22A12MRGPRX4TRPM4MAP2K1 | |
| SCHEMBL394617 | 0.79 | XDH (0.46) | XDHSLC22A12MRGPRX4TRPM4MAP2K1 | |
| SCHEMBL31084678 | 0.78 | XDH (0.45) | XDHSLC22A12MRGPRX4TRPM4MAP2K1 | |
| SCHEMBL16632529 | 0.78 | SMN1; SMN2 (0.52) | MRGPRX4 | |
| SCHEMBL11434090 | 0.75 | XDH (0.43) | XDHSLC22A12MRGPRX4TRPM4MAP2K1 | |
| SCHEMBL28219660 | 0.74 | PTPN1 (0.49) | XDHSLC22A12MRGPRX4TRPM4HTT | |
| SCHEMBL3157619 | 0.73 | XDH (0.53) | XDHSLC22A12TRPM4MAP2K1HTT | |
| SCHEMBL508503 | 0.72 | TSHR (0.57) | XDHSLC22A12MRGPRX4TRPM4MAP2K1 | |
| SCHEMBL6834830 | 0.71 | FLT1 (0.37) | XDHSLC22A12TRPM4HTTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | XDH 70/4885SLC22A12 2889/4885MRGPRX4 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.